(Reuters) – Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries.
Based on current treatment patterns, the vast majority of patients are expected to receive a five-day treatment course using six vials of remdesivir, which equates to $2,340 per patient, the company said.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)
